CTSL and cancer: Together, from these two datasets, it appears that ACE2/TMPRSS2 have transient elevation with cancer treatments that resolve in less than 20 days post-treatment, while CTSL exhibits a prolonged elevation at for at least 4–6 weeks post-treatment.